Shell Asset Management CO Novavax Inc Transaction History

Shell Asset Management CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$36.28 - $75.29 $71,943 - $149,300	-1,983 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$134.56 - $217.97 $78,852 - $127,730	586 Added 41.95%	1,983 $284,000
Q3 2021 Nov 04, 2021	SELL	$177.8 - $270.58 $57,251 - $87,126	-322 Reduced 18.73%	1,397 $290,000
Q2 2021 Aug 12, 2021	SELL	$121.0 - $257.67 $291,126 - $619,954	-2,406 Reduced 58.33%	1,719 $365,000
Q1 2021 May 10, 2021	SELL	$112.98 - $319.93 $171,955 - $486,933	-1,522 Reduced 26.95%	4,125 $748,000
Q3 2020 Nov 13, 2020	BUY	$79.44 - $178.51 $68,874 - $154,768	867 Added 18.14%	5,647 $612,000
Q2 2020 Aug 10, 2020	BUY	$13.86 - $83.61 $66,250 - $399,655	4,780 New	4,780 $398,000

291

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $704M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

Stay updated on Shell Asset Management CO with notifications on news.